These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 23766362)

  • 1. Tivantinib (ARQ197) displays cytotoxic activity that is independent of its ability to bind MET--letter.
    Rimassa L; Bruix J; Broggini M; Santoro A
    Clin Cancer Res; 2013 Aug; 19(15):4290. PubMed ID: 23766362
    [No Abstract]   [Full Text] [Related]  

  • 2. Tivantinib (ARQ197) displays cytotoxic activity that is independent of its ability to bind MET--response.
    Michieli P; Basilico C; Pennacchietti S
    Clin Cancer Res; 2013 Aug; 19(15):4291. PubMed ID: 23766360
    [No Abstract]   [Full Text] [Related]  

  • 3. Tivantinib (ARQ197) displays cytotoxic activity that is independent of its ability to bind MET.
    Basilico C; Pennacchietti S; Vigna E; Chiriaco C; Arena S; Bardelli A; Valdembri D; Serini G; Michieli P
    Clin Cancer Res; 2013 May; 19(9):2381-92. PubMed ID: 23532890
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted therapies: Tivantinib--a cytotoxic drug in MET inhibitor's clothes?
    Michieli P; Di Nicolantonio F
    Nat Rev Clin Oncol; 2013 Jul; 10(7):372-4. PubMed ID: 23712183
    [No Abstract]   [Full Text] [Related]  

  • 5. Tivantinib (ARQ 197) exhibits antitumor activity by directly interacting with tubulin and overcomes ABC transporter-mediated drug resistance.
    Aoyama A; Katayama R; Oh-Hara T; Sato S; Okuno Y; Fujita N
    Mol Cancer Ther; 2014 Dec; 13(12):2978-90. PubMed ID: 25313010
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tivantinib induces G2/M arrest and apoptosis by disrupting tubulin polymerization in hepatocellular carcinoma.
    Xiang Q; Zhen Z; Deng DY; Wang J; Chen Y; Li J; Zhang Y; Wang F; Chen N; Chen H; Chen Y
    J Exp Clin Cancer Res; 2015 Oct; 34():118. PubMed ID: 26458953
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytotoxic activity of tivantinib (ARQ 197) is not due solely to c-MET inhibition.
    Katayama R; Aoyama A; Yamori T; Qi J; Oh-hara T; Song Y; Engelman JA; Fujita N
    Cancer Res; 2013 May; 73(10):3087-96. PubMed ID: 23598276
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergistic activity of the c-Met and tubulin inhibitor tivantinib (ARQ197) with pemetrexed in mesothelioma cells.
    Leon LG; Gemelli M; Sciarrillo R; Avan A; Funel N; Giovannetti E
    Curr Drug Targets; 2014; 15(14):1331-40. PubMed ID: 25483224
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tivantinib (ARQ197) in hepatocellular carcinoma.
    Porta C; Giglione P; Ferrari A; Reversi F; Liguigli W; Imarisio I; Ganini C
    Expert Rev Anticancer Ther; 2015 Jun; 15(6):615-22. PubMed ID: 26035719
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tivantinib inhibits the VEGF signaling pathway and induces apoptosis in gastric cancer cells with c-MET or VEGFA amplification.
    Kim BJ; Kim YJ; Sohn SH; Kim B; Sul HJ; Kim HS; Zang DY
    Invest New Drugs; 2020 Dec; 38(6):1633-1640. PubMed ID: 32361789
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting the pro-survival protein MET with tivantinib (ARQ 197) inhibits growth of multiple myeloma cells.
    Zaman S; Shentu S; Yang J; He J; Orlowski RZ; Stellrecht CM; Gandhi V
    Neoplasia; 2015 Mar; 17(3):289-300. PubMed ID: 25810013
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase 1 study of the c-Met inhibitor, tivantinib (ARQ197) in children with relapsed or refractory solid tumors: A Children's Oncology Group study phase 1 and pilot consortium trial (ADVL1111).
    Geller JI; Perentesis JP; Liu X; Minard CG; Kudgus RA; Reid JM; Fox E; Blaney SM; Weigel BJ
    Pediatr Blood Cancer; 2017 Nov; 64(11):. PubMed ID: 28449393
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tivantinib (ARQ-197) exhibits anti-tumor activity with down-regulation of FAK in oral squamous cell carcinoma.
    Xi WH; Yang LY; Cao ZY; Qian Y
    Biochem Biophys Res Commun; 2015 Feb; 457(4):723-9. PubMed ID: 25623532
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tivantinib: critical review with a focus on hepatocellular carcinoma.
    Rota Caremoli E; Labianca R
    Expert Opin Investig Drugs; 2014 Nov; 23(11):1563-74. PubMed ID: 25307444
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structures of a diverse set of colchicine binding site inhibitors in complex with tubulin provide a rationale for drug discovery.
    Wang Y; Zhang H; Gigant B; Yu Y; Wu Y; Chen X; Lai Q; Yang Z; Chen Q; Yang J
    FEBS J; 2016 Jan; 283(1):102-11. PubMed ID: 26462166
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase 2 multicenter study of tivantinib (ARQ 197) monotherapy in patients with relapsed or refractory germ cell tumors.
    Feldman DR; Einhorn LH; Quinn DI; Loriot Y; Joffe JK; Vaughn DJ; Fléchon A; Hajdenberg J; Halim AB; Zahir H; Motzer RJ
    Invest New Drugs; 2013 Aug; 31(4):1016-22. PubMed ID: 23417696
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Allosteric inhibition of c-Met kinase in sub-microsecond molecular dynamics simulations induced by its inhibitor, tivantinib.
    Yan M; Wang H; Wang Q; Zhang Z; Zhang C
    Phys Chem Chem Phys; 2016 Apr; 18(15):10367-74. PubMed ID: 27029952
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tivantinib, a new option for second-line treatment of advanced hepatocellular carcinoma? The experience of Italian centers.
    Rimassa L; Santoro A; Daniele B; Germano D; Gasbarrini A; Salvagni S; Masi G; Abbadessa G; Lamar M; Goldberg T; Porta C
    Tumori; 2015; 101(2):139-43. PubMed ID: 25838254
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Response to crizotinib in a patient with MET-mutant papillary renal cell cancer after progression on tivantinib.
    Stein MN; Hirshfield KM; Zhong H; Singer EA; Ali SM; Ganesan S
    Eur Urol; 2015 Feb; 67(2):353-4. PubMed ID: 25457019
    [No Abstract]   [Full Text] [Related]  

  • 20. Tivantinib in hepatocellular carcinoma.
    Trojan J; Zeuzem S
    Expert Opin Investig Drugs; 2013 Jan; 22(1):141-7. PubMed ID: 23167786
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.